钠-葡萄糖协同转运蛋白2抑制剂对心血管系统影响的研究进展

Research Progress of Sodium-Glucose Transporter 2 Inhibitors' Effects on Cardiovascular System

钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂是一类新型的抗高血糖药物,该药通过抑制肾小管上皮细胞SGLT2的功能以减少尿中葡萄糖的重吸收,从而达到降低血糖的目的。该药除了降血糖,还具有降低血压、体质量及尿酸水平,改善血脂异常等心血管危险因素的作用,对心血管系统有较好的保护作用,且不良反应小、安全可靠。该类药物在国外上市以来受到广泛关注,随着对药物研究的深入,其作用机制及不良反应也越来越明确,应用也将越来越广泛。

Sodium-glucose cotransporters 2 （SGLT2） inhibitors are a new class of antidiabetic agents. By inhibiting thefunction of SGLT2 in renal tubular epithelial cells, the drugs can reduce the re-absorption of glucose in urine, thereby reac-hing the hypoglycemic goal. In addition to the hypoglycemic effect, the drug can also reduce the body weight, blood pressureand uric acid, and improve dyslipidemia and other cardiovascular risk factors, presenting a good protective effect on the car-diovascular system, with less adverse effect and good safety and reliability. Such drugs are widely concerned since marketingin oversea market. With the further study on these agents, the mechanism and adverse effects are getting clearer, and theapplication will be more extensive.